Customized Monoclonal Antibody Design Highlighted at the AACC Clinical Lab Expo
|
By LabMedica International staff writers Posted on 31 Jul 2013 |
|
Image: Customized monoclonal antibodies by MedixMAB by Design (Photo courtesy of Medix Biochemica).
Biotech researchers and other life scientists working with monoclonal antibodies (MABs) who are attending the AACC (American Association for Clinical Chemistry) Clinical Lab Expo in Houston (TX, USA), from July 30-August 1, 2013, are invited to learn how to exploit the services of an innovative developer and producer of custom-made recombinant antibodies.
Medix Biochemica (Kauniainen, Finland), producer of monoclonal antibodies for the global IVD industry and of proprietary rapid diagnostic tests, is highlighting its MedixMAB by Design antibody production service at the Clinical Lab Expo.
By offering a completely customized service for the in vitro generation of high-performance monoclonal recombinant antibodies and Fab fragments, MedixMAB by Design paves the way for the development of superior IVD assays. Antibodies are produced to the strictest international quality standards, and this new service gives IVD manufacturers access to topflight biological without the need to invest in costly production facilities and expertise.
Medix makes monoclonal antibodies using an advanced in vitro system, which incorporates the latest in cutting-edge phage display-production technology. These antibodies can target a broad range of antigens, including poorly immunoreactive and toxic compounds. Successful recombinant antibodies can then easily be produced in bulk quantities. Alternatively, Fab fragments, which greatly enhance specificity and sensitivity of solid-phase IVD assays, can be generated in just three months. All development and manufacturing processes are comprehensively regulated and documented, adhering to ISO 9001, ISO 13485 and [US] FDA QSR quality standards.
Maija Partanen, product manager for MedixMAB by Design, said, “With 30 years of experience in antibody production technology, Medix Biochemica provides the IVD industry with outstanding diagnostic performance. Our fast and flexible, quality-assured MedixMAB by Design service enables IVD manufacturers to offer the next generation of IVD assay, with superior sensitivity and specificity, at minimal cost.”
Related Links:
Medix Biochemica
Medix Biochemica (Kauniainen, Finland), producer of monoclonal antibodies for the global IVD industry and of proprietary rapid diagnostic tests, is highlighting its MedixMAB by Design antibody production service at the Clinical Lab Expo.
By offering a completely customized service for the in vitro generation of high-performance monoclonal recombinant antibodies and Fab fragments, MedixMAB by Design paves the way for the development of superior IVD assays. Antibodies are produced to the strictest international quality standards, and this new service gives IVD manufacturers access to topflight biological without the need to invest in costly production facilities and expertise.
Medix makes monoclonal antibodies using an advanced in vitro system, which incorporates the latest in cutting-edge phage display-production technology. These antibodies can target a broad range of antigens, including poorly immunoreactive and toxic compounds. Successful recombinant antibodies can then easily be produced in bulk quantities. Alternatively, Fab fragments, which greatly enhance specificity and sensitivity of solid-phase IVD assays, can be generated in just three months. All development and manufacturing processes are comprehensively regulated and documented, adhering to ISO 9001, ISO 13485 and [US] FDA QSR quality standards.
Maija Partanen, product manager for MedixMAB by Design, said, “With 30 years of experience in antibody production technology, Medix Biochemica provides the IVD industry with outstanding diagnostic performance. Our fast and flexible, quality-assured MedixMAB by Design service enables IVD manufacturers to offer the next generation of IVD assay, with superior sensitivity and specificity, at minimal cost.”
Related Links:
Medix Biochemica
New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
New
Cytomegalovirus Real-Time PCR Test
Quanty CMV Virus System
New
Silver Member
Fixed Speed Tube Rocker
GTR-FS
Latest AACC 2013 News
- Beckman Coulter Launches Newest Version of Remisol Advance at AACC
- Beckman Coulter's New Solutions Demonstrated at 2013 AACC Annual Meeting
- Solutions Designed for Labs to Reduce Costs and Improve Productivity Showcased at the AACC Expo
- Latest Generation Random Analyzer System Unveiled at the AACC Clinical Lab Expo
- Ultrasensitive Troponin-I Assay to Be Introduced at the AACC Clinical Lab Expo
- Customized Assays Assembled Using Digital Molecular Barcoding Chemistry
- Advanced Hospital Robot Courier Debuts at the AACC Clinical Lab Expo
- Researchers Will Have Ready Access to Molecular Diagnostics Expertise at the AACC Clinical Lab Expo
- Hybrid Random Access Analyzer on Display at AACC's Clinical Lab Expo
- DCN Diagnostics and Asahi Kasei Fibers Launch Market Collaboration
- Quantitative Test for ß-Hydroxybutyrate Assesses Diabetic Ketoacidosis
Channels
Clinical Chemistry
view channel
AI-Powered Blood Test Accurately Detects Ovarian Cancer
Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more
Automated Decentralized cfDNA NGS Assay Identifies Alterations in Advanced Solid Tumors
Current circulating cell-free DNA (cfDNA) assays are typically centralized, requiring specialized handling and transportation of samples. Introducing a flexible, decentralized sequencing system at the... Read more
Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read moreMolecular Diagnostics
view channel
Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD
Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more
First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis
Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more
New Molecular Label to Help Develop Simpler and Faster Tuberculosis Tests
Tuberculosis (TB), the deadliest infectious disease globally, is responsible for infecting an estimated 10 million people each year and causing over 1 million deaths annually. While chest X-rays and molecular... Read more
Biomarker Discovery Paves Way for Blood Tests to Detect and Treat Osteoarthritis
The number of individuals affected by osteoarthritis is projected to exceed 1 billion by 2050. The primary risk factor for this common, often painful chronic joint condition is aging, and, like aging itself,... Read moreHematology
view channel
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read more
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Microbiology
view channel
Molecular Stool Test Shows Potential for Diagnosing TB in Adults with HIV
Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, led to 1.25 million deaths in 2023, with 13% of those occurring in people living with HIV. The current primary diagnostic method for... Read more
New Test Diagnoses Bacterial Meningitis Quickly and Accurately
Bacterial meningitis is a potentially fatal condition, with one in six patients dying and half of the survivors experiencing lasting symptoms. Therefore, rapid diagnosis and treatment are critical.... Read more
Pathology
view channel
Groundbreaking Chest Pain Triage Algorithm to Transform Cardiac Care
Cardiovascular disease is responsible for a third of all deaths worldwide, and chest pain is the second most common reason for emergency department (ED) visits. With EDs often being some of the busiest... Read more
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read more
Technology
view channel
Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
